What is NADAC in Hospice Pharmacy?
NADAC (National Average Drug Acquisition Cost) is a pricing benchmark published by CMS that reflects the average price pharmacies pay for medications based on real invoice data.
In hospice pharmacy, NADAC is used to improve pricing transparency, align reimbursement with actual drug acquisition costs, and reduce reliance on outdated benchmarks like AWP (Average Wholesale Price).
For hospice executives, NADAC represents a shift toward real-world pricing visibility and financial alignment.
Why Hospice Drug Costs Are So Difficult to Control
Hospice operates under a fixed per diem reimbursement model, which creates a unique financial dynamic:
- Revenue is capped per patient per day
- Drug utilization varies significantly by patient
- Clinical needs are unpredictable
- Pharmacy costs are one of the largest variable expenses
- Increased medication quantities driven by patient complexity
This makes hospice drug costs both high-impact and difficult to manage. Historically, the problem has been compounded by opaque pricing models, including:
- AWP-based reimbursement structures
- Spread pricing arrangements
- Hidden administrative fees
- Limited cost visibility at the patient level
The result is a system where many hospice leaders cannot confidently answer: “What are we actually paying for medications—and why?”
The Financial Impact of Poor Pharmacy Visibility in Hospice
For hospice executives, pharmacy is not just a clinical function. It is a direct financial driver. Even small variations in drug spend can significantly impact margin due to the fixed per diem reimbursement model.
Consider this:
- A $1.00 increase in PPD drug cost
- Across 100 patients
- Over 30 days
- That results in $3,000 in additional monthly cost, or $36,000 annually.
Now scale that across larger census sizes or multi-site operations, and the impact becomes material. What makes this more challenging is that many organizations do not identify these changes in real time. Without visibility into per-unit drug cost, PPD trends, or pricing consistency, financial impact often goes unnoticed until it is reflected in margin compression. This is why predictability and transparency are not just operational goals. They are financial requirements.
Does NADAC Reduce Hospice Drug Costs?
NADAC improves pricing transparency and aligns reimbursement with actual acquisition costs. More importantly, it establishes a consistent, reliable pricing foundation that removes the distortions created by legacy benchmarks.
Hospice organizations that move from AWP-based pricing to NADAC-based pricing typically see:
- Greater clarity into drug costs
- Reduced pricing distortion
- Improved financial alignment
The key shift is this: NADAC is not just a better benchmark. It is a fundamentally more accurate representation of drug cost reality.
Why NADAC Changes Financial Behavior, Not Just Pricing
One of the most overlooked impacts of NADAC is that it does not just improve pricing accuracy. It changes how hospice organizations understand and manage pharmacy spend. Under AWP-based models, pricing is often abstract. Discounts are applied to an inflated benchmark, making it difficult to interpret true cost performance. This creates a reliance on contract structure rather than actual financial insight.
NADAC shifts this dynamic. By aligning pricing to real acquisition cost, hospice leaders gain a clearer understanding of how medication spend behaves across their organization. This enables:
- More accurate financial forecasting
- Better alignment between clinical utilization and cost
- Increased confidence in pharmacy reporting
- Greater accountability across pharmacy relationships
Instead of managing pharmacy as a variable expense, organizations begin to manage it as a measurable and controllable financial component.
The Evolution of Hospice Pharmacy Pricing Models
To understand NADAC’s role, hospice leaders need clarity on how pricing models have evolved.
AWP-Based Models
In AWP-based pricing, contracts are built around a published benchmark that does not reflect true acquisition cost. This creates a system where discounts appear meaningful, but the underlying benchmark is inflated. As a result, pricing can look competitive on paper while still being misaligned with reality.
Spread Pricing Models
In spread pricing, PBMs charge hospice organizations more than they reimburse pharmacies, keeping the difference as profit. This creates three core issues:
- Lack of visibility into true cost
- Misaligned incentives between stakeholders
- Difficulty validating pricing accuracy
Pass-Through Models
Pass-through models aim to improve transparency by eliminating spread pricing. However, they may still include administrative fees, variable pharmacy performance, and limited enforcement mechanisms. This means transparency improves, but predictability may still be inconsistent.
NADAC-Based Models
NADAC represents a meaningful advancement by grounding pricing in actual pharmacy acquisition data. This shift alone significantly improves transparency, financial alignment, and cost accuracy.
NADAC in Hospice: What It Solves
- Improved PBM Transparency: NADAC replaces theoretical pricing with real acquisition cost data, making pharmacy pricing easier to interpret.
- Alignment with Market Reality: Because it reflects pharmacy invoice data, NADAC better represents actual drug costs in the market.
- Financial Standardization: It creates a common reference point across hospice, pharmacy, and PBM relationships.
Why NADAC-Based Pricing Drives the Lowest Per-Unit Cost
One of the most important advantages of NADAC is its direct alignment to pharmacy acquisition cost. Unlike AWP-based pricing, which is inflated and disconnected from reality, NADAC is grounded in what pharmacies actually pay.
This is why NADAC-based pricing represents the lowest per-unit cost model. Rather than relying on adjusted or discounted benchmarks, NADAC establishes pricing at its most accurate and fundamental level.
How Pricing Accuracy Impacts Total Cost of Care
In hospice, drug pricing is often evaluated at the unit level. However, the true impact of pricing accuracy is realized across the total cost of care. When pricing is misaligned, even slightly, the effect compounds across high-frequency medications, larger patient populations, and extended lengths of stay.
By contrast, when pricing is aligned to NADAC:
- Each medication reflects a more accurate cost basis
- Variability is reduced at scale
- Total pharmacy spend becomes more predictable
Over time, this consistency improves budget accuracy, margin stability, and long-term financial planning. For hospice executives, this is where pricing transitions from a tactical concern to a strategic advantage.
What Is Hospice PPD Drug Spend?
Hospice drug costs are most accurately measured as per patient per day (PPD). PPD represents the average daily medication cost per patient and is the most relevant metric to demonstrate hospice medication utilization.
Why PPD Matters
PPD allows hospice leaders to:
- Align drug costs with revenue
- Identify trends and outliers
- Forecast financial performance
- Make informed operational decisions
What Is a Good Hospice PPD Benchmark?
High-performing hospice pharmacy models often achieve less than $7.00 PPD drug spend. Achieving this level typically requires NADAC-aligned pricing, elimination of spread pricing, full transparency, and strong operational controls.
How PPD Visibility Changes Executive Decision-Making
Many hospice organizations track overall pharmacy spend, but far fewer have clear visibility into PPD performance trends. When executives can see PPD in real time, they can:
- Identify cost changes early
- Understand utilization patterns
- Compare performance across locations
- Forecast financial outcomes
Without consistent PPD visibility, leadership relies on retrospective reporting and limited insight. With it, pharmacy becomes a manageable and optimizable component of the business.
Real-World Example: Why NADAC?
Consider two hospice organizations.
| Organization | Contract Type | Outcome |
| Organization A | AWP-Based | Pricing appears structured but lacks accuracy and transparency. |
| Organization B | NADAC-Based | Improved transparency, stronger financial alignment, and clearer cost visibility. |
Key Takeaway: The difference is not operational complexity. The difference is NADAC.
NADAC vs Traditional PBM Pricing in Hospice
| Model | Transparency | Predictability | Cost Accuracy |
| AWP-based pricing | Low | Low | Low |
| NADAC-based pricing | High | High | High |
How MaxHaven Applies NADAC in Hospice Pharmacy
MaxHaven leverages NADAC as the foundation for a fully aligned pharmacy model:
- NADAC-Based, Lowest Per-Unit Cost: Pricing aligns to NADAC while ensuring the lowest possible per-unit cost.
- No Spread Pricing or Hidden Markups: The model eliminates spread pricing, hidden fees, and revenue leakage.
- Full PPD Visibility: Hospice organizations gain clear insight into per patient per day drug spend. Most partners achieve average drug costs below $7.00 PPD.
- Operational Alignment: MaxHaven introduces enforced service standards and centralized accountability. This ensures pricing performs as expected in real-world execution.
Why PBM Transparency Matters More Than Ever
Hospice providers face regulatory pressure, margin compression, and rising drug costs. Without transparency, pharmacy becomes unpredictable. Without control, it becomes a liability. NADAC changes that by providing a clear, standardized pricing foundation.
What Hospice Executives Should Evaluate in Pharmacy Pricing Models
As hospice organizations evaluate pharmacy partnerships and pricing models, the focus should extend beyond contract structure. Key questions to consider include:
- Is pricing aligned to actual acquisition cost? Models based on NADAC provide a more accurate foundation than those built on inflated benchmarks.
- Do we have clear visibility into PPD performance? Without visibility into per patient per day drug spend, it is difficult to assess financial performance or identify trends.
- Can we confidently explain cost changes? Leadership should be able to clearly understand what is driving increases or decreases in pharmacy spend.
- Is pricing standardized across the organization? Variation across locations or patient populations can introduce unnecessary financial risk.
- Does the model support long-term financial predictability? Consistency over time is more valuable than short-term pricing advantages.
Organizations that can confidently answer these questions are better positioned to control drug spend, improve forecasting accuracy, and strengthen operational performance.
The Executive Takeaway
NADAC answers the most important question in hospice pharmacy: “What do drugs actually cost?” By aligning pricing to real acquisition cost, NADAC enables transparency, financial consistency, and a predictable cost structure. For hospice leaders, this is the foundation for better decision-making and stronger financial performance.
How Lack of Pharmacy Control Impacts Hospice Operations Beyond Cost
While drug spend is often viewed through a financial lens, the impact of pharmacy variability extends well beyond cost. For hospice organizations, inconsistency in pharmacy performance can directly affect:
Clinical Coordination
When pricing models lack alignment or consistency, pharmacies may adjust sourcing, substitutions, or fulfillment patterns. This can create variability in medication availability, which in turn affects care team coordination. Even small disruptions can lead to:
- Delays in therapy initiation
- Increased nurse intervention time
- Additional communication across care teams
- Decrease in patient satisfaction
- Impacted relationships with patient referral sources
Staff Efficiency
Without clear, predictable pharmacy performance, hospice staff often compensate operationally. This may include increased time spent resolving medication issues, additional follow-up with pharmacy providers, and manual tracking of inconsistencies. Over time, these inefficiencies reduce productivity and increase administrative burden.
Caregiver and Patient Experience
Hospice care is highly sensitive to timing and reliability. When pharmacy performance is inconsistent, it can lead to delays in medication delivery, confusion around prescriptions, and increased stress for caregivers. While these issues may originate from pricing or operational misalignment, they ultimately affect the patient experience.
Leadership Confidence and Decision-Making
Perhaps most importantly, lack of visibility and control reduces confidence at the leadership level. When executives cannot clearly answer why costs are changing, what is driving variability, and whether performance is aligned with expectations, decision-making becomes reactive instead of strategic. This is why pharmacy is not just a cost center. It is a core operational component that requires structure, visibility, and accountability.
Why Enforcement Matters More Than Transparency Alone
One of the most common misconceptions in hospice pharmacy is that transparency alone will solve pricing challenges. Transparency is necessary, but it is not sufficient.
Without enforcement:
- Pricing agreements may not be consistently applied
- Performance expectations may not be met
- Variability can persist without clear accountability
- Spread pricing can occur
This creates a gap between what is contractually defined and what is operationally delivered. Enforcement closes that gap. It ensures that pricing aligns with expectations, performance is measurable, and deviations are identified and corrected. For hospice executives, this is where true control is established.
Building a Pharmacy Strategy That Supports Long-Term Stability
As hospice organizations continue to grow and adapt, pharmacy strategy must evolve alongside broader operational goals. A strong pharmacy strategy should support:
- Financial Stability: Predictable drug spend aligned with reimbursement structures.
- Operational Consistency: Reliable performance across all patient populations and locations.
- Scalability: The ability to maintain performance as census grows or expands geographically.
- Data-Driven Decision Making: Access to real-time insights that inform both clinical and financial strategies.
Organizations that treat pharmacy as a strategic function—not just a vendor relationship—are better positioned to manage risk, improve outcomes, and maintain financial stability over time.
FAQ: NADAC and Hospice Drug Costs
- What is NADAC in hospice pharmacy? A CMS benchmark reflecting average pharmacy acquisition cost used to improve transparency.
- Does NADAC eliminate spread pricing? No, unless explicitly removed.
- What is PPD? Per patient per day drug cost, the most important hospice pharmacy metric.
- What is a strong benchmark? Many high-performing hospices achieve under $7.00 PPD.
- Why is PBM transparency important? It eliminates hidden costs and improves predictability.
- Can NADAC still include hidden fees? Yes, depending on contract structure.
- How can hospices reduce drug costs? Through transparency, PPD tracking, no spread pricing, and operational control.
- How does MaxHaven help? By combining NADAC pricing, no hidden costs, PPD visibility, and accountability.
Final Thought
NADAC represents one of the most important advancements in hospice pharmacy pricing. It replaces uncertainty with clarity and distortion with accuracy. For hospice organizations, that shift is not incremental. It is foundational.
